Table 2. Association of the 1100delC and I157T variants of the CHEK2 gene with patients with unselected prostate cancer or HPC.

Mutation and sample	No. of carriers/total (frequency)	OR	95% CI	P
1100delC
Controls	2/480 (0.4%)	1.00
Patients with unselected  Prostate cancer	7/537 (1.3%)	3.14	0.65−15.16	0.15
Patients with HPC	4/120 (3.3%)	8.24	1.49−45.54	0.02a
I157T
Controls	26/480 (5.4%)	1.00
Patients with unselected  Prostate cancer	42/537 (7.8%)	1.48	0.89−2.46	0.13
Patients with HPC	13/120 (10.8%)	2.12	1.06−4.27	0.04a

^aStatistically significant.